Journal of Radiation Industry (방사선산업학회지)

Korean Society of Radiation Industry (한국방사선산업학회)
권호 표지
DOI QR코드

DOI QR Code

Verification of the Cancer Therapeutic Efficacy of Lutetium-177 Using Gene Expression

유전자 발현을 활용한 루테튬 (177Lu)의 암 치료 효능 검증

  • Da-Mi Kim (Radioisotope Research Division, Korea Atomic Energy Research Institute) ;
  • So-Young Lee (Radioisotope Research Division, Korea Atomic Energy Research Institute) ;
  • Jae-Cheong Lim (Radioisotope Research Division, Korea Atomic Energy Research Institute) ;
  • KangHyuk Choi (Radioisotope Research Division, Korea Atomic Energy Research Institute)
  • 김다미 (한국원자력연구원 동위원소연구부) ;
  • 이소영 (한국원자력연구원 동위원소연구부) ;
  • 임재청 (한국원자력연구원 동위원소연구부) ;
  • 최강혁 (한국원자력연구원 동위원소연구부)
  • Received : 2023.11.08
  • Accepted : 2023.12.15
  • Published : 2023.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

Lutetium(177Lu), with its theranostic properties, is one of the most widely used radioisotopes and has a large share of the radiopharmaceutical market due to its many applications and targeted therapeutic research using lutetium-based radiopharmaceuticals. However, lutetium-based radiopharmaceuticals currently approved by the US Food and Drug Administration (FDA) are limited to the indications of gastrointestinal cancer, pancreatic neuroendocrine cancer and metastatic castration-resistant prostate cancer. To overcome these limitations, we aimed to demonstrate the feasibility of expanding the use of lutetium-based radiopharmaceuticals by verifying the availability and therapeutic efficacy of lutetium produced in a research reactor(HANARO). In this study, we confirmed the therapeutic efficacy of lutetium by using cancer cells from different types of cancer. In addition, we selected cancer biomarkers based on characteristics common to various cancer cells and compared and evaluated the therapeutic efficacy of lutetium by regulating the expression of target genes. The results showed that modulation of cancer biomarker gene expression resulted in higher therapeutic efficacy compared to lutetium alone. In conclusion, this study verified the potential use and therapeutic efficacy of lutetium based on the production of a research reactor (HANARO), providing fundamental evidence for the development of lutetium-based radiopharmaceuticals and the expansion of their indications.

Keywords

Acknowledgement

본 연구는 과학기술정보통신부의 재원으로 한국원자력연구원 주요사업(방사성동위원소 응용 표준화 기술 개발, 524440-23)의 일환으로 수행되었습니다.

References

  1. Maydelid TN, Enrique MA, Pedro CN, Kattesh VK and Blanca OG. 2021. Nanoradiopharmaceuticals based on alpha emitters: recent developments for medical applications. Pharmaceutics 13(8):1123. https://doi.org/10.3390/pharmaceutics13081123. 
  2. George S, Lisa B, Michael RM and Jessie RN. 2020. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat. Rev. Drug. Discov. 19:589-608. https://doi.org/10.1038/s41573-020-0073-9. 
  3. Jiajia Z, Shanshan Q, Mengdie Y, Xiaoyi Z, Shenghong Z and Fei Y. 2023. Alpha-emitters and targeted alpha therapy in cancer treatment. iRADIOLOGY 1:245-261. https://doi.org/10.1002/ird3.30. 
  4. Rafael N, Robert MFZ, Artur MC, Felipe GB, Marcelo TS, Jose FGM and Carlos AB. 2021. General concepts in theranostics. PET Clin. 16(3):313-326. https://doi.org/10.1016/j.cpet.2021.03.010. 
  5. Jose FGM, Rafael FN, Artur MC, Elaine CZ, Larissa BC, Felipe GB, Marcelo Q, Giovanni GC and Carlos AB. 2020. Theranostics in nuclear medicine: Emerging and reemerging integrated imaging and therapies in the era of precision oncology. Radiographic 40(6):1715-1740. https://doi.org/10.1148/rg.2020200021. 
  6. Suliman S, Ajnas A, Wijdan A and Aisyah E. 2022. Radiopha-maceutical treatments for cancer therapy, radionuclides charateristics, applications, and challenges. Molecules 27(16):5231. https://doi.org/10.3390/molecules27165231. 
  7. Chiara G, Crixtina T and Alessandra B. 2021. Radiation resistance: A matter of transcription factor. Front Oncol. 11:662840. https://doi.org/10.3389/fonc.2021.662840. 
  8. Krishnan V and Ito Y. 2017. A regulatory role for RUNX1, RUNX3 in the maintenance of genome integrity. Adv. Exp. Med. Biol. 962:491-510. https://doi.org/10.1007/978-981-10-3233-2_29. 
  9. George SC and Samuel EJJ. 2023. Developments in 177Lu-based radiopharmaceutical therapy and dosimetry. Font. Chem. 11:1218670. https://doi.org/10.3389/fchem.2023.1218670. 
  10. Typhanie L, Julie F, Elise L, Damien P, Cedric D and Jonathan V. 2023. Safety and therapeutic optimization of Lutetium-177 based radiopharmaceuticals. Pharmaceutics 15(4):1240. https://doi.org/10.3390/pharmaceutics15041240. 
  11. Ute H and Klaus K. 2019. Lutathera®: The first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy. Pharmaceuticals (Basel) 12(3):114. https://doi.org/10.3390/ph12030114. 
  12. Jaleh F, Sundeep A, Haley G, Mallorie HF, Sriram S, Christy J, Wei C, Tiffany KR, Gang N, Anthony F, Min W, Kelly C, William FP, Daniel LS, Shenghui T, Richard P, Laleh A-K, Amna I and Paul GK. 2023. FDA approval summary: Lutetium Lu177 vipivotide tetraxetant for patients with metastatic castration resistant prostate cancer. Clin. Cancer Res. 29(9):1651-1657. https://doi.org/10.1158/1078-0432.CCR-22-2875. 
  13. Ito Y, Bae SC and Chuang LS. 2015. The RUNX3 family: developmental regulators in cancer. Nat. Rev. Cancer 15:81-95. https://doi.org/10.1038/nrc3877. 
  14. Zhang C, Chen H, Deng Z, Long D, Xu L and Liu Z. 2020. DGCR8/miR-106 axis enhances radiosensitivity of head and neck squamous cell carcinomas by downregulating RUNX3. Front Med. (Lausanne) 7:582097. https://doi.org/10.3389/fmed.2020.582097. 
  15. Krishnan V and Ito Y. 2017. A regulatory role for RUNX1, RUNX3 in the maintenance of genome integrity. Adv. Exp. Med. Biol. 962:491-510. https://doi.org/10.1007/978-981-10-3233-2_29. 
  16. Kim DM, Lee SY, Lee JC, Cho EH and Park UJ. 2023. RUNX3 regulates the susceptibility against EGFR-targeted non-small cell lung cancer therapy using 47Sc-conjugated cetuximab. BMC Cancer 23:652. https://doi.org/10.1186/s12885-023-11161-1. 
  17. Delong L. 2019. Cancer biomarkers for targeted therapy. Biomarker Research 7:25. https://doi.org/10.1186/s40364-019-0178-7. 
  18. Lee YS, Lee JW, Jang JW, Chi XZ, Kim JH, Li YH, Kim MK, Kim DM, Choi BS, Kim EG, Chung JH, Lee OJ, Lee YM, Suh JW, Chuang LSH, Ito Y and Bae SC. 2013. RUNX3 inactivation is a crucial early event in the development of lung adenocarcinoma. Cancer Cell 24(5):603-616. https://doi.org/10.1016/j.ccr.2013.10.003. 
  19. Lee JY, Lee JW, Park TG, Han SH, Yoo SY, Jung KM, Kim DM, Lee OJ, Kim DH, Chi XZ, Kim EG, Lee YS and Bae SC. 2023. Runx3 restoration regresses k-ras-activated mouse lung cancers and inhibits recurrence. Cells 12(20):2438. https://doi.org/10.3390/cells12202438.